Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) Director Sells 620 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 620 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the transaction, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tempus AI Stock Performance

Shares of TEM opened at $41.00 on Friday. The stock has a 50-day moving average of $52.64. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. First Horizon Advisors Inc. bought a new position in Tempus AI in the 3rd quarter worth $30,000. Sandia Investment Management LP purchased a new position in shares of Tempus AI in the second quarter valued at about $136,000. Vestor Capital LLC bought a new position in shares of Tempus AI in the third quarter worth about $153,000. Stifel Financial Corp purchased a new stake in shares of Tempus AI during the third quarter worth about $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Tempus AI during the 3rd quarter valued at approximately $258,000. 24.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on TEM. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Guggenheim began coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital raised their price target on Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Finally, Wolfe Research started coverage on Tempus AI in a research report on Friday. They set an “outperform” rating and a $60.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.